Weekly injectable diabetes medications
Pro Research Analysisby 
Searched over 200M research papers
Weekly Injectable Diabetes Medications: Adherence and Patient Preferences
Improved Medication Adherence and Persistence with Weekly Injections
Research consistently shows that patients with type 2 diabetes are more likely to stick with their medication when using once-weekly injectable treatments compared to daily injections. Studies found that once-weekly glucagon-like peptide-1 receptor agonists (GLP-1 RAs) lead to higher rates of adherence and persistence, meaning patients continue their treatment for longer and take it as prescribed more often than those on daily regimens Weeda2021Polonsky2021. This improved adherence is important because it can lead to better blood sugar control and overall health outcomes Weeda2021Polonsky2021.
Patient Preferences: Weekly vs. Daily Injections
Patients strongly prefer weekly injections over daily ones. The frequency of injections is the most important factor influencing their choice of treatment, even more than needle size or injection pain. People using weekly injections or those not yet on injectables are especially likely to choose a weekly option if given the choice . Even when considering different device features, the convenience of fewer injections stands out as a key driver of patient satisfaction Hauber2016Matza2017.
Efficacy and Safety of Weekly Injectable Medications
Once-weekly GLP-1 RAs, such as exenatide and semaglutide, have been shown to provide sustained reductions in HbA1c (a measure of blood sugar control) and body weight over time Diamant2014Ludvik2021Amamoo2023+1 MORE. For example, studies of semaglutide found significant decreases in both HbA1c and weight after one year of use in real-world settings Amamoo2023Amamoo2024. Weekly GLP-1 RAs also tend to have a lower risk of hypoglycemia (dangerously low blood sugar) compared to daily insulin Diamant2014Ludvik2021.
A new weekly insulin, icodec, has shown similar glucose-lowering effects and safety compared to daily insulin glargine in people with type 2 diabetes who have not previously used insulin . In type 1 diabetes, weekly icodec was as effective as daily insulin degludec for blood sugar control, though it was associated with a higher rate of hypoglycemia .
Quality of Life and Treatment Burden
Weekly injections are associated with a small reduction in quality of life compared to oral medications, but the difference is minor. The main factors that can slightly lower quality of life are the need to mix the medication, wait during preparation, and handle needles. However, these drawbacks are generally outweighed by the convenience of fewer injections .
Conclusion
Weekly injectable diabetes medications, especially GLP-1 RAs and new weekly insulins, offer significant advantages in adherence, patient preference, and sustained blood sugar control compared to daily injections. Patients overwhelmingly prefer weekly regimens, which can lead to better long-term health outcomes. While there are minor inconveniences related to injection preparation, the overall benefits make weekly injectables an attractive option for many people with diabetes.
Sources and full results
Most relevant research papers on this topic